Affilogic is a privately-owned biotech company specialized in discovery and development of a novel class of affinity proteins called Nanofitins®. They are potent antibody-mimetics, exhibiting high affinity and specificity for capture and targeting of biomolecules. Affilogic has designed Nanofitins® against 40+ targets to date. Biotherapies based on Nanofitins®’ technology are currently under development with Ferring Pharmaceuticals, Bind Therapeutics and other pharmaceutical laboratories.
Produits et services
Nanofitins® also demonstrate many small molecule-like attributes such as a very small size (7 kDa, around 20 times smaller than a monoclonal antibody), an extreme robustness and better tissue penetration. Deriving from a naturally hyperstable scaffold, Nanofitins® are resistant to temperature and pH. Several on-going research programs aim at overcoming antibodies’ limitations and outperforming current targeted therapies by allowing local delivery formulations, single-gene multi-specific molecules and Nanofitin®-Drug-Conjugates.
- Adresse : 2 rue de la Houssinière
- Dirigeant : Olivier, KITTEN
- Forme juridique : SAS
- Capital : 60000
- NAF : 7211Z
- Creation date : 07/02/2010
- Effectif : 15
- Couverture géographique : Worldwide